TauroPace
-
How TauroPace™ can reduce CIED infections.
The key active component in TauroPace™ is taurolidine, which works by preventing and disrupting biofilm formation. It inhibits microbial adhesion to surfaces and actively damages microbial cell membranes and associated toxins. 1
Taurolidine is a derivative of the amino acid taurine and functions as a broad-spectrum antimicrobial agent, demonstrating activity against a wide range of bacteria and fungi. 2
TauroPaceTM is a trademark of TauroPharm GmbH and is distributed by Kimal PLC only in the UK.
1. Wouters, Y., et al. (2018). Randomised clinical trial: 2% taurolidine versus 0.9% saline locking in patients on home parenteral nutrition. Alimentary Pharmacology & Therapeutics, [online] 48(4), pp.410–422. doi:https://doi.org/10.1111/apt.14904.
2. Liu, Y., et al. (2013). Taurolidine Lock Solutions for the Prevention of Catheter-Related Bloodstream Infections: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLoS ONE, 8(11), p.e79417. doi:https://doi.org/10.1371/journal.pone.0079417
-
For more information, please click on the webinar recordings below.